Eli Radiopharma Raises Over RMB 100 Million Angel+ Round to Accelerate Radiopharmaceutical Innovation and Clinical Translation

Hangzhou, China - September 25, 2025 - Hangzhou Eli Radiopharma Co., Ltd. (“Eli Radiopharma”, “the Company”), an innovative radiopharmaceutical company dedicated to the integrated diagnosis and therapeutics of cancer and neurological diseases, today announced the completion of an extended angel financing round of over RMB 100 million. The round was co-led by Huaige Capital, CTS Capital, and KHK Fund, with participation from new investors CSPC & Growth Bio Fund, SNDVC-Rongsheng Venture, Lizhi Investment, and Honghou Capital, as well as existing shareholder BOHE Angel Fund. The funds will be used to advance Eli Radiopharma's core pipelines toward clinical development, enhance the Company's R&D infrastructure and technology platform, and expand the team with scientific talents.

A few months ago, Eli Radiopharma completed an angel round of RMB 100 million. The two consecutive financing rounds demonstrate strong investor confidence in the Company’s strategy, scientific capabilities, and potential long-term development. Eli Radiopharma leverages its expertise in ligand discovery, molecular optimization, and clinical translation to advance a robust pipeline of radiopharmaceuticals into clinical development, aiming to deliver innovative diagnostic and therapeutic solutions for patients with cancer and neurological diseases.

"We are deeply grateful to our investors for their recognition and trust in Eli Radiopharma's long-term development," said Dr. Feng Yu, Founder and CEO of Eli Radiopharma. " This financing marks a significant milestone in the Company's growth, which will accelerate the clinical translation of our core pipelines. We will continue to deepen our 'core-and-dual-engine' strategy by simultaneously advancing our R&D infrastructure and technology platform, and building a capable and experienced core team to drive its growth. We will remain focused on addressing unmet medical needs and advancing innovative radiopharmaceuticals to provide more precise and effective treatments for patients with cancer and neurological diseases.

Dr. Du Jiangbo, Managing Partner of Investment of Huige Capital, said: "We have a strong conviction in Eli Radiopharma's strategic vision and strong execution in advancing innovative radiopharmaceuticals. With significant potential in theranostics, Eli Radiopharma's core pipeline addresses critical unmet medical needs. Huige Capital is delighted to establish a deep partnership with Eli Radiopharma and will continue to support the acceleration of its clinical translation to bring innovative treatment options to patients worldwide."

Song Zhang, Founding Partner of CTS Capital, said: “As an investor in Eli Radiopharma's previous round, we are delighted to see the remarkable achievements the Company has made in a short period in terms of pipeline advancement, team expansion, and strategic execution. And the decision to increase our investment stems from the company's demonstrated strong market confidence in its technology and potential. CTS Capital will leverage its biopharmaceutical ecosystem to support Eli Radiopharma's innovation, accelerate clinical development, and accompany the Company on its long-term journey.”"

Jie Hua, Partner & General Manager of the Healthcare Investment at KHK Fund, said: "Radioligand Therapy (RLT) demonstrates high clinical value and commercial potential in oncology and neurological diseases. Eli Radiopharma has established a comprehensive platform for the discovery, screening, optimization, and validation of novel ligands—including small molecules, cyclic peptides, and antibody fragments—while also leveraging its advantages in β- and α-emitting radionuclides. The team's deep domain knowledge, systematic approach, and platform-driven capability enable the rapid target optimization and validation across a balanced pipeline. KHK Fund is pleased to be closely involved in Eli Radiopharma's early development as a long-term partner, working together to build a more diverse and innovative biopharma ecosystem."

About Eli Radiopharma

Eli Radiopharma, founded in 2024, is a radiopharmaceutical company specializing in innovating and developing radiopharmaceuticals and advanced technology applications. Driven by its core value 'innovation-driven precision medicine', Eli Radiopharma is focused on delivering integrated diagnostic and therapeutic solutions for oncology and neuroscience. By combining molecular targeting with radionuclide technology, Eli Radiopharma is committed to developing safe and cutting-edge radiopharmaceuticals to provide precise diagnostics and effective treatments to improve the health and longevity of patients worldwide.

About Huige Capital

Huaige Capital is a professional investment institution focusing on the healthcare and biotechnology sectors, with offices in Shanghai and Chengdu. The team possesses extensive industry background and experience in entrepreneurship/private equity investment and capital operations. Guided by the philosophy of "Attracting from Afar, Uniting from Near; Investigating Things, Extending Knowledge", Huaige Capital adopts a dual-drive investment strategy of "VC Investment" and "Industrial Empowerment" to create maximum investment value for both investors and portfolio companies.

Since its establishment, the fund has invested in over 30 high-quality enterprises, including INT Medical (1501.HK), Cofoe Medical (301087.SZ), Leads Biolabs (9887.HK), Affinity Biopharma, Resproly (874344.NQ), HuaJian Science, Hyperway Pharmaceuticals, Juncell Therapeutics, Yineng Pharmaceutical, among others.

About CTS Capital

CTS Capital is a multi-stage healthcare and life sciences investment firm. Managed by a team of seasoned professionals with deep insights into the healthcare industry and extensive expertise in private equity, CTS Capital is committed to partnering with exceptional entrepreneurs and scientists, and actively engaging in the growth of its portfolio companies to drive technological and commercial innovations in China's healthcare sector and the global market. Guided by a research-driven investment strategy, CTS Capital's investment focus spans biotechnology, innovative therapeutics, innovative medical devices, precision diagnosis, healthcare services, and other cutting-edge technologies within the broader healthcare landscape.

Since its inception, CTS Capital has invested in several leading companies in their respective sectors, including United Imaging (688271.SH), SinoCellTech (688520.SH), SinoBiological (301047.SZ), Ascentage Pharma (06855.HK), Giant Biogene (02367.HK), and LaNova Medicines (Sino Biopharm (01177.HK) Wholly-owned acquisition).

About KHK Fund

KHK Fund is a private equity and venture capital manager registered with the Asset Management Association of China (AMAC). KHK Fund is a sector-focused investor, targeting high-growth opportunities in deep tech (e.g., smart manufacturing, new energy, semiconductors, AI) and healthcare. The strategy of capitalizing on technological innovation and industrial upgrading allows KHK Fund to deliver a strong track record. Notable portfolio companies include Enflame Technology, MetaX, ESWIN, AVATR, Syneron Bio, TandemAI, and YolTech Therapeutics, among others.